Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) traded down 7.8% during mid-day trading on Wednesday . The stock traded as low as $8.53 and last traded at $8.53, with a volume of 52,156 shares changing hands. The stock had previously closed at $9.25.

A number of analysts have recently weighed in on the company. BMO Capital Markets assumed coverage on Neos Therapeutics in a research report on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price objective for the company. Wells Fargo & Co. reissued a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. Zacks Investment Research cut Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Finally, Royal Bank Of Canada lowered their price objective on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research report on Tuesday, May 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $21.75.

The company has a 50 day moving average price of $9.84 and a 200 day moving average price of $10.10. The stock’s market capitalization is $135.10 million.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.08. Equities analysts forecast that Neos Therapeutics Inc. will post ($4.88) earnings per share for the current year.

In other Neos Therapeutics news, Director Alan L. Heller bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 19th. The shares were purchased at an average price of $7.61 per share, with a total value of $76,100.00. Following the completion of the acquisition, the director now directly owns 379,888 shares of the company’s stock, valued at approximately $2,890,947.68. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Presidio Partners 2007, L.P. sold 57,968 shares of the stock in a transaction on Friday, April 15th. The shares were sold at an average price of $10.23, for a total value of $593,012.64. Following the completion of the transaction, the insider now directly owns 1,623,997 shares in the company, valued at approximately $16,613,489.31. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP raised its stake in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent reporting period.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.